InvestorsHub Logo
icon url

daemon57

12/18/20 8:28 AM

#134335 RE: jimmy667 #134333

jimmy667 - echo your sentiment on price +$5 for RH type traders and other FOMO. + a few $ for institutional base if we get uplisted.
Can't wait for HIV to be accepted and a PH2/3 for basket/NASH.
Hot dog there are going be some millionaires on this board....

GLTU/A.
icon url

TheBigTicket

12/18/20 8:28 AM

#134337 RE: jimmy667 #134333

$20-$30 per share on Covid

HIV approval $50-$60

icon url

dadbrotheroftwins

12/18/20 8:32 AM

#134338 RE: jimmy667 #134333

I believe you are right. What if HIV gets approval in 2021? How much do you think that could add?
icon url

3X Charm

12/18/20 5:58 PM

#134519 RE: jimmy667 #134333

Does your half account for income risk? ( not arguing want to know your thoughts). With the vaccine rollout-the near term may produce non repeatable revenue; future income from any COVID play could be much lower than projected by NP for 2021. If CYDY can rollout HIV quickly that could offset revenue loss from COVID, but we do not know how quickly HIV use will be adopted by doctors and patients. The default for may people is to not change.